Table 4. Multivariate Cox proportional hazards regression model predicting duration of longest PFS.
| Clinical Feature | Hazard Ratio | 95% CI | P-value |
|---|---|---|---|
| Age* | 0.99 | 0.97-1.01 | 0.179 |
| Race (Non-Caucasian vs. Caucasian) | 1.32 | 0.83-2.09 | 0.243 |
| Tumor histology group§ (Recommended vs. not recommended) | 0.72 | 0.43-1.21 | 0.215 |
| Bevacizumab -containing regimen (Yes vs. no) | 2.50 | 1.00-6.29 | 0.051 |
| P53 Status (Mutation vs. wild type) | 2.65 | 1.57-4.47 | <0.001 |
| P53 mutation status and bevacizumab therapy interaction | 0.15 | 0.05-0.44 | <0.001 |
*
Age as continuous variable, § Recommended versus not recommended means dichotomized into tumor histologies for which bevacizumab is or is not FDA-approved